BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 24661317)

  • 21. Cutaneous effects of BRAF inhibitor therapy: a case series.
    Mattei PL; Alora-Palli MB; Kraft S; Lawrence DP; Flaherty KT; Kimball AB
    Ann Oncol; 2013 Feb; 24(2):530-537. PubMed ID: 23035153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors.
    Vigarios E; Lamant L; Delord JP; Fricain JC; Chevreau C; Barrés B; Gomez-Roca C; Boulanger M; Sibaud V
    Br J Dermatol; 2015 Jun; 172(6):1680-1682. PubMed ID: 25495246
    [No Abstract]   [Full Text] [Related]  

  • 23. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients.
    Boussemart L; Routier E; Mateus C; Opletalova K; Sebille G; Kamsu-Kom N; Thomas M; Vagner S; Favre M; Tomasic G; Wechsler J; Lacroix L; Robert C
    Ann Oncol; 2013 Jun; 24(6):1691-7. PubMed ID: 23406731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.
    Casadevall D; Vidal J; Gallardo F; Zuccarino F; Arumí-Uría M; Dalmases A; Bellosillo B; Montagut C
    J Med Case Rep; 2016 Jun; 10(1):158. PubMed ID: 27255157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor.
    Galliker NA; Murer C; Kamarashev J; Dummer R; Goldinger SM
    Eur J Dermatol; 2015 Apr; 25(2):177-80. PubMed ID: 25788221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dermatological approach to vemurafenib skin toxicity: a single centre experience.
    Fava P; Marra E; Astrua C; Brizio M; Cavaliere G; Quaglino P; Fierro MT; Savoia P
    G Ital Dermatol Venereol; 2016 Feb; 151(1):25-31. PubMed ID: 25296968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.
    Maldonado-Seral C; Berros-Fombella JP; Vivanco-Allende B; Coto-Segura P; Vazquez-Lopez F; Perez-Oliva N
    Dermatol Online J; 2013 Apr; 19(4):16. PubMed ID: 24021375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.
    Anforth R; Menzies A; Byth K; Carlos G; Chou S; Sharma R; Scolyer RA; Kefford R; Long GV; Fernandez-Peñas P
    J Am Acad Dermatol; 2015 May; 72(5):809-15.e1. PubMed ID: 25748298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dabrafenib and its potential for the treatment of metastatic melanoma.
    Menzies AM; Long GV; Murali R
    Drug Des Devel Ther; 2012; 6():391-405. PubMed ID: 23251089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
    Capovilla M
    Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma.
    Park JJ; Hawryluk EB; Tahan SR; Flaherty K; Kim CC
    JAMA Dermatol; 2014 Mar; 150(3):307-11. PubMed ID: 24352115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Panniculitis With Necrotizing Granulomata in a Patient on BRAF Inhibitor (Dabrafenib) Therapy for Metastatic Melanoma.
    Ramani NS; Curry JL; Kapil J; Rapini RP; Tetzlaff MT; Prieto VG; Torres-Cabala CA
    Am J Dermatopathol; 2015 Aug; 37(8):e96-9. PubMed ID: 25839886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF inhibitor activity in V600R metastatic melanoma.
    Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
    Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Don't miss the base - keratoacanthoma-type squamous cell carcinoma with perineural invasion during BRAF inhibitor therapy for melanoma.
    Schüürmann M; Pönitzsch I; Simon JC; Ziemer M
    J Dtsch Dermatol Ges; 2015 Dec; 13(12):1279-81. PubMed ID: 26612802
    [No Abstract]   [Full Text] [Related]  

  • 37. Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy.
    Yin VT; Wiraszka TA; Tetzlaff M; Curry JL; Esmaeli B
    Ophthalmic Plast Reconstr Surg; 2015; 31(4):e112-5. PubMed ID: 24833447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors.
    Falchook GS; Rady P; Konopinski JC; Busaidy N; Hess K; Hymes S; Nguyen HP; Prieto VG; Bustinza-Linares E; Lin Q; Parkhurst KL; Hong DS; Sherman S; Tyring SK; Kurzrock R
    Arch Dermatol Res; 2016 Jul; 308(5):357-65. PubMed ID: 27098388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations.
    Ponti G; Pellacani G; Tomasi A; Gelsomino F; Spallanzani A; Depenni R; Al Jalbout S; Simi L; Garagnani L; Borsari S; Conti A; Ruini C; Fontana A; Luppi G
    J Clin Pathol; 2013 May; 66(5):441-5. PubMed ID: 23463675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds.
    Bellón T; Lerma V; González-Valle O; González Herrada C; de Abajo FJ
    Br J Dermatol; 2016 Mar; 174(3):621-4. PubMed ID: 26412570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.